Combination of Naltrexone and Isotretinoin for the Treatment of Darier Disease (Abstract)

Combination of Naltrexone and Isotretinoin for the Treatment of Darier Disease Cureus 03 January 2023 https://www.cureus.com/articles/130848-combination-of-naltrexone-and-isotretinoin-for-the-treatment-of-darier-disease Darier disease (DD) is an autosomal-dominant genodermatosis in which mutations in the ATP2A2 gene result in impaired intercellular adhesion and epidermal blistering. Treatment options usually rely on systemic retinoids, but a refractory disease is still a therapeutical challenge. Given […]

Thyroid, Diet, and Alternative Approaches (Abstract)

Thyroid, Diet, and Alternative Approaches J Clin Endocrinol Metab 23 November 2022 https://pubmed.ncbi.nlm.nih.gov/35952387/ Background: Increasingly, patients are asking their physicians about the benefits of dietary and alternative approaches to manage their diseases, including thyroid disease. We seek to review the evidence behind several of the vitamins, minerals, complementary medicines, and elimination diets that patients are […]

Off-label pharmacological treatment for neuropathic pain… (Abstract)

Off-label pharmacological treatment for neuropathic pain: A Delphi study by the Spanish Pain Society Neuropathic Pain Task Force Pain Pract 29 October 2022 https://pubmed.ncbi.nlm.nih.gov/36308490/ Objectives: The use of off-label pharmacotherapies for neuropathic pain (NP) is growing relating to the many unmet needs of patients. However, clinical guidelines fail to address it, and the available evidence […]

Antinociceptive effect of ultra-low dose naltrexone in a pre-clinical model of postoperative orofacial pain (Abstract)

Antinociceptive effect of ultra-low dose naltrexone in a pre-clinical model of postoperative orofacial pain Brain Res 04 November 2022 https://pubmed.ncbi.nlm.nih.gov/36335995/ Pain management after oral surgeries is essential to enhance recovery, reduce negative outcomes and improve the experience of the patient. Naltrexone (NTX) is a non-selective opioid receptor antagonist that has been shown to modulate neuro-inflammation […]

Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic (Abstract)

Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic Int Immunopharmacol 09 November 2022 https://pubmed.ncbi.nlm.nih.gov/36379151/ Persons with multiple sclerosis (PwMS) have been considered at high risk for vaccination and/or acquisition of COVID-19 related to their reduced immune systems and daily regimen of immune suppressing therapy. Substantiated and unsubstantiated reports on these […]

A Comprehensive Review: Chronic Pain Sequelae in the Presence of Ehlers-Danlos Syndrome (Abstract)

A Comprehensive Review: Chronic Pain Sequelae in the Presence of Ehlers-Danlos Syndrome Curr Pain Headache Rep 25 November 2022 https://pubmed.ncbi.nlm.nih.gov/36434419/ Purpose of review: Patients diagnosed with Ehlers-Danlos syndromes (EDS), and especially those with the hypermobility subtype, often experience a diverse range of acute and chronic pain conditions throughout their lifetime. These can present in a […]

Novel Therapies for Centralized Pain: a Brief Review (Abstract)

Novel Therapies for Centralized Pain: a Brief Review Curr Pain Headache Rep 28 September 2022 https://pubmed.ncbi.nlm.nih.gov/36169808/ Purpose of review: Centralized pain presents a complex pathology that many classic pharmacological agents for pain have not been able to sufficiently treat. To date, there are no clear guidelines for preferred treatment methods or comprehensive protocol that addresses […]

A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder (Abstract)

A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder Trials 30 September 2022 https://pubmed.ncbi.nlm.nih.gov/36175917/ Background: Major depressive disorder (MDD) is a leading cause of disability worldwide. The current treatments are ineffective in approximately one-third of patients, resulting in a large economic burden and reduced quality […]

Ultra-low dose naloxone restores the antinocicepitve effect of morphine in… (Abstract)

Ultra-low dose naloxone restores the antinocicepitve effect of morphine in PTX-treated rats: association of IL-10 upregulation in the spinal cord Life Sci 04 September 2012 https://pubmed.ncbi.nlm.nih.gov/22820166/ Aims: Ultra-low dose naloxone has been shown to restore the antinociceptive effect of morphine in pertussis toxin (PTX)-treated rats by suppressing spinal microglia activation and inhibiting inflammatory cytokine expression. […]

Ultra-low dose naloxone upregulates interleukin-10 expression and… (Abstract)

Ultra-low dose naloxone upregulates interleukin-10 expression and suppresses neuroinflammation in morphine-tolerant rat spinal cords Behav Brain Res 11 February 2010 https://pubmed.ncbi.nlm.nih.gov/19799935/ Co-infusion of ultra-low dose naloxone and morphine attenuates morphine tolerance through the prevention of mu opioid receptor-Gs protein coupling. We previously demonstrated that chronic intrathecal infusion of morphine leads to tolerance and spinal neuroinflammation. The […]